HPR237 Price Determinants and Pricing Policies Concerning Potentially Innovative Health Technologies: A Scoping ReviewN Xander, CA Uyl‐de Groot, O Groene et al.|Value in Health|2024Cited by 0
Price determinants and pricing policies concerning potentially innovative health technologies: a scoping reviewN Xander, Carin A. Uyl‐de Groot, Frederick W. Thielen et al.|The European Journal of Health Economics|2025Cited by 0
Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: The ASCERTAIN projectCarin A. Uyl-de Groot, Eline Aas, N Xander et al.|Health Policy and Technology|2026Cited by 0
Bridging affordability and sustainability of health innovations via novel pricing, cost-effectiveness, and reimbursement models to improve patient access: the ASCERTAIN projectCarin A. Uyl-de Groot, Eline Aas, N Xander et al.|London School of Economics and Political Science Research Online (London School of Economics and Political Science)|2026Cited by 0
Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The NetherlandsYansi Wu, Gauthier Quinonez, Maureen Rutten-van Mölken et al.|OSF Preprints (OSF Preprints)|2026Cited by 0